Neoclarityn

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
Variation type IB /	This was an application for a variation	26/02/2026		SmPC and PL	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

EMA/VR/0000312765	following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted To update the wording related to drowsiness in Section 1 of the Package Leaflet to ensure full alignment with the information already included in the Summary of Product Characteristics (SmPC). In addition, following the recommendation in procedure WS/1834 for the above-mentioned products a reformulation, of the paediatric information included in Section 4.8 of the SmPC. This update is intended to bring the paediatric subsection fully in line with the SmPC guideline. The Applicant is also taking this opportunity to revise the list of local representatives for Czech Republic, Denmark, Iceland, Norway, and Poland, and to remove the information related to the United Kingdom (Northern Ireland).				
Variation type IB / EMA/VR/0000312574	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2 Change in test procedure for active substance or starting	15/01/2026			

	material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted				
Variation type IB / EMA/VR/0000301280	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted	15/01/2026			
Variation type IA / EMA/VR/0000268887	A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph.	14/05/2025			

	Eur. Monograph - B.III.1.a.4 Deletion of certificates (in case multiple certificates exist per material) - Accepted				